Home › Trials › NCT06446271
Clinical trial Recruiting at 1 site Observational Ages 10 and up

Investigating biomarkers in patients with genetic cardiomyopathy

Official title: Biomarkers in SCOTland CardiomyopatHy Registry

Run by NHS Greater Glasgow and Clyde · NCT06446271 · Data updated 2026-11-12

This study is trying to find new markers in blood and other tests to help identify people with a family history of genetic heart disease who might develop symptoms, so they can be monitored more easily and effectively.

More Cardiomyopathies trials

Quick facts

Study typeObservational
Ages10 Years and up
SexAll
Enrollment750 (estimated)
SponsorNHS Greater Glasgow and Clyde
Academic / other
Locations1 site (Glasgow)
StatusRecruiting
StartedJune 26, 2024
Main results expectedMarch 19, 2027
Study endsMarch 19, 2027
Registry record updatedJuly 3, 2024
Trial IDNCT06446271 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include males and females aged 10 years and older with a pathogenic or likely pathogenic variant in cardiomyopathy-related genes.

Probably not a fit

Patients who are unable to consent or have severe non-cardiac diseases that significantly reduce life expectancy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on identifying existing and novel biomarkers in patients with a personal or family history of specific gene variants associated with cardiomyopathy. It aims to differentiate between individuals who will develop cardiomyopathy and those who will not, thereby improving risk stratification and clinical surveillance. By analyzing blood, urine, electrocardiographic, and imaging biomarkers, the study seeks to replace the need for frequent and costly monitoring through traditional imaging techniques. The ultimate goal is to enhance patient management and outcomes in those affected by genetic cardiomyopathy.

Why it matters

Potential benefit: If successful, this study could lead to more efficient monitoring and early detection of cardiomyopathy in genetically predisposed individuals.

How similar studies have gone: Other studies have shown promise in using biomarkers for genetic conditions, but this specific approach is novel in the context of cardiomyopathy.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Male or female ≥10 years of age
* Written informed consent / assent
* Pathogenic or likely pathogenic variant in a cardiomyopathy gene (TTN, LMNA, MYBPC3, DSP, FLNC) or undergoing predictive genetic testing (if negative these people would be invited to enter the control arm)

Exclusion Criteria:

* Unable to consent.
* Geographical / social reasons preventing attending study centre
* Unable to complete study assessments.
* Severe non-cardiac disease expected to reduce life expectancy \< 5 years
* Current participation in a blinded drug interventional trial (or treatment within 4 weeks)

Where it's running

  • Queen Elizabeth University Hospital
    Glasgow, United Kingdom     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Cardiomyopathies 54Genetic Predisposition 35NHS Greater Glasgow and Clyde 15
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.